Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
Is a
Allocation Type
Non-Randomized
0
Intervention Model
Sequential Assignment
0
Intervention Name
Tocilizumab
0
Baricitinib
0
Low molecular weight heparin
0
Dexamethasone
0
Dornase Alfa Inhalant Product
0
Anakinra 100Mg/0.67Ml Inj Syringe
0
Interventional Trial Phase
Not Applicable
0
Interventional Trial Purpose
Treatment
0
Intervention Type
Drug
0
Last Updated
March 15, 2022
0
Masking Type
None (Open Label)
0
Primary Completion Date
November 30, 2021
0
Trial Recruitment Size
150
0
Trial Sponsor
Clinical Trial Start Date
October 25, 2020
0
Study Completion Date
December 31, 2023
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
Combined Administration of Inhaled DNase, Baricitinib and Tocilizumab as Rescue Treatment in Severe COVID-19 Patients
0
Official Website
Find more entities like Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
